Effects of methamphetamine on HIV in treated individuals
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease
This study is looking at how using methamphetamine affects people living with HIV who are on treatment, to better understand the challenges they face in managing their health and working towards an HIV cure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11123501 on NIH RePORTER |
What this research studies
This research investigates how methamphetamine (MA) use affects HIV-infected individuals who are receiving antiretroviral therapy. It focuses on understanding both short-term and long-term impacts of MA on viral transcription and immune function. Participants will be enrolled in a longitudinal study to assess the relationship between MA use and residual HIV production, inflammation, and immune responses. The goal is to identify specific challenges faced by HIV-positive individuals who also use methamphetamine, which may hinder efforts to achieve an HIV cure.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-positive adults who are currently on antiretroviral therapy and have a history of methamphetamine use.
Not a fit: Patients who are not HIV-positive or those who do not have a history of methamphetamine use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for HIV-positive individuals who use methamphetamine, potentially enhancing their immune function and overall health outcomes.
How similar studies have performed: Previous studies have indicated that methamphetamine use can exacerbate HIV-related immune dysfunction, suggesting that this research builds on established findings rather than exploring an entirely novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Lee, Sulggi Angela — University of California, San Francisco
- Study coordinator: Lee, Sulggi Angela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.